Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hafslund Nycomed's non-US contrast agent sales up 20%

This article was originally published in Clinica

Executive Summary

Hafslund Nycomed, the Norwegian pharmaceutical and contrast agent manufacturer, has reported 20% higher contrast agent sales through its distribution network outside the US in 1994. In the US the company says competition in the diagnostic imaging market has intensified but the company's market share has been maintained in the X-ray field and increased within MRI. Last July, Nycomed boosted its contrast agent division with the purchase of Sterling Winthrop's imaging business from Sanofi (see Clinica No 610, p 14) and achieved a leading position in this market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT090593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel